Drugs / DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS)

Trials 8

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT01891136 Apr 2004 → Nov 2014 — University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 23 trials · 2 met primary
Phase 2 NCT01904604 Sep 2013 → Aug 2015 food allergy National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary
Phase 2 NCT01197053 Aug 2010 → Feb 2015 food allergy Assistance Publique - Hôpitaux de Paris Completed No outcome recorded
Phase 2 NCT00329784 Dec 2006 → May 2014 dermatitis, food allergy National Institute of Allergy and Infectious Diseases (NIAID) Completed Met primary
Phase 33 trials · 1 met primary
Phase 3 NCT07003919 Jun 2025 → Nov 2026 expected food allergy DBV Technologies Recruiting No outcome recorded
Phase 3 NCT05741476 Feb 2023 → Nov 2025 overdue food allergy DBV Technologies Active not recruiting Met primary
Phase 3 NCT03859700 Dec 2018 → May 2025 food allergy DBV Technologies Completed No outcome recorded
Phase not stated1 trial
— NCT05424731 — food allergy DBV Technologies Available No outcome recorded
Comparator or background therapy2 trials
Phase 2 NCT03907397 Comparator Aug 2019 → Nov 2023 food allergy Scott Sicherer Completed No outcome recorded
Phase 2 NCT02103270 Comparator Apr 2014 → Jul 2018 food allergy Stanford University Completed No outcome recorded

News releases announcing trial results or a regulatory action · 6

DateIssuerRelease
2026-02-28 DBV Technologies Results DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting dbv-technologies.com ↗
Approximately 83% of children treated with the VIASKIN ® Peanut Patch increased their eliciting dose at month 12, compared to approximately 48% in the placebo group
2025-12-16 DBV Technologies Results DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years dbv-technologies.com ↗
2024-07-30 DBV Technologies Regulatory DBV Technologies Provides Updates on the Viaskin Peanut Program in Children and Toddlers and Reports Second Quarter and Half-Year 2024 Financial Results dbv-technologies.com ↗
DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA’s protocol queries regarding patch wear-time in COMFORT Toddlers
2023-11-09 DBV Technologies Results DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers dbv-technologies.com ↗
Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters.
2023-05-10 DBV Technologies Results DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers dbv-technologies.com ↗
2023-04-19 DBV Technologies Regulatory DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA dbv-technologies.com ↗
In the written responses received, the Agency confirmed that the Company’s Phase 3 EPITOPE study met the pre-specified criteria for success for the primary endpoint.

All press releases naming this drug 10 releases

DateIssuerRelease

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as DEFATTED POWDER OF ARACHIS HYPOGAEA L., SEMEN (PEANUTS) ChEMBL registry synonym — accepted as the source's own label CHEMBL5315089 ↗
Known as DBV712 “Fifty-two (52) children from 5 to 17 years of age with a confirmed peanut allergy during a baseline double blind placebo-controlled food challenge (DBPCFC) (reacting to a...” NCT01197053 ↗
5

NCT01904604 ↗

NCT07003919 ↗

NCT03859700 ↗

NCT05741476 ↗

NCT05424731 ↗

Known as Palforzia ChEMBL registry synonym — accepted as the source's own label CHEMBL5315089 ↗
Known as Peanut Protein “Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.” NCT00329784 ↗
3

NCT03907397 ↗

NCT02103270 ↗

NCT01891136 ↗

Known as Peanut protein flour ChEMBL registry synonym — accepted as the source's own label CHEMBL5315089 ↗
Modality Protein / enzyme biologic “2 g of peanut protein” NCT00329784 ↗
Route Oral “consume 2 g of peanut protein” NCT00329784 ↗